NCT06713057

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

Precision Medicine Applied to Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer Using Tumor Derived Organoids and In-vitro Sensitivity Testing: a Phase 2, Single-center, Open-label, and Non-comparative Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: West China Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The current study aims to explore the potential advantages of chemotherapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced or metastatic poorly differentiated or anaplastic thyroid cancer who have undergone conventional therapy in the past or unresectable patients .

Detailed description

This research trial aims to determine the efficacy of organoid-guided chemotherapy for patients with locally advanced or metastatic poorly differentiated or anaplastic thyroid cancer. Currently, there are numerous clinical trials evaluating various molecularly targeted therapies for refractory, poorly differentiated thyroid cancer. Preoperative personalized targeted neoadjuvant therapy has been established as a critical approach in managing advanced thyroid cancer. However, clinical trials investigating personalized chemotherapy to guide the treatment of thyroid cancer remain scarce. Tumor organoids represent a sophisticated three-dimensional pathological model that preserves the histological and molecular characteristics of the original tumor. These models can be utilized to assess the in vitro efficacy of multiple anticancer drugs. The investigators' objective is to validate the effectiveness and safety of selecting and processing chemotherapeutic agents through drug susceptibility testing, thereby ensuring pragmatic and precise treatment tailored to individual patients' needs. The investigators will also investigate the variables affecting the effectiveness of chemotherapy that is guided by organoids. Additionally, side effects related to the medication are also studied.

Conditions

• Locally Advanced Thyroid Gland Carcinoma
• Thyroid Cancer

Interventions

Type	Name	Description
DRUG	Cyclophosphamide+Pemetrexed+5-Fluorouracil	IV or PO
DRUG	Cyclophosphamide+Doxorubicin+5-Fluorouracil	IV or PO
DRUG	Vindesine + Cisplatin	IV or PO
DRUG	Doxorubicin + Cisplatin	IV or PO
DRUG	Doxorubicin + Cyclophosphamide + Cisplatin	IV or PO
DRUG	Docetaxel + Doxorubicin	IV or PO
DRUG	Paclitaxel + Carboplatin	IV or PO
DRUG	Paclitaxel + Doxorubicin	IV or PO
DRUG	Paclitaxel + Cisplatin	IV or PO
DRUG	Gemcitabine alone	IV or PO

Timeline

• Start date: 2024-12-01
• Primary completion: 2025-12-01
• Completion: 2026-07-01
• First posted: 2024-12-03
• Last updated: 2024-12-03

Locations

1 site across 1 country: China